




RECORD

09-14-2001

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

101843270

al documents or copy thereof

To the Honorable Commissioner of Patents and

1. Submission Type:

- ☐ New
☐ Resubmission (Non-Recordation) Document ID#
☐ Correction of PTO Error
Reel # _____ Frame # _____
☒ Corrective Document
Reel # 011668 Frame # 0245, 0246, 0247, 0248

Data Element in Question :

PLEASE CORRECT INVENTOR'S NAME.

2. Conveyance

- ☒ Assignment ☐ Security Agreement
☐ License ☐ Change of Name
☐ Merger ☐ Other _____

US. GOVERNMENT

(For Use ONLY by U.S. Government Agencies)

- ☐ Departmental File ☐ Secret File

Total No. of pages of conveyance document including attachments _____

4. Name of conveying party(ies):

- ¹Johnson, Barry L.
²Patel, Mona
³Rodgers, James D.
⁴Wang, Haisheng
⁵Tarby, Christine M.
⁶Bakthavatchalam, Rajagopal

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

Execution Date: ¹12/18/2000 ²12/22/2000
³12/18/2000 ⁴12/18/2000
⁵12/18/2000 ⁶01/03/2001

5. Name and address of receiving party(ies):

DUPONT PHARMACEUTICALS COMPANY
CHESTNUT RUN PLAZA
974 CENTRE ROAD
WILMINGTON, DELAWARE 19805

Additional name(s) & address(es) attached? ☐ Yes ☒ No

5. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s): **09/691,249**

B. Patent No.(s):

Docket No.: **PH-7104**Additional numbers attached: ☐ Yes ☒ No

6. Correspondent Name & Address:

MARY K. VANATTEN
E. I. DU PONT DE NEMOURS AND COMPANY
LEGAL-PATENTS
1007 MARKET STREET
WILMINGTON, DELAWARE 19898

7. Total number of applications and patents involved: 1

8. Total fee (37 CFR 3.41) \$40.00

- ☐ Enclosed (Check No.: _____)
☒ Authorized to be charged to deposit account

9. Deposit account number: 04-1928

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

10. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

CAROL REEDER

SENIOR LEGAL CLERK

Signature

Date

09/13/2001 LNUELLER 00000312 041928 09691249

01 FC581

40.00 CH

Total number of pages comprising cover sheet: 1PATENT
REEL: 012151 FRAME: 0309

04-16-2001

CORDATION FORM COVER SHEET
PATENTS ONLYU.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

3.73.01

101674135

s and Trademarks: Please record the attached original documents or copy thereof

<p>1. Submission Type:</p> <p><input checked="" type="checkbox"/> New</p> <p><input type="checkbox"/> Resubmission (Non-Recordation) Document ID# _____</p> <p><input type="checkbox"/> Correction of PTO Error Reel # _____ Frame # _____</p> <p><input type="checkbox"/> Corrective Document Reel # _____ Frame # _____</p> <p>Data Element in Question : _____</p>	<p>2. Conveyance Type:</p> <p><input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Security Agreement</p> <p><input type="checkbox"/> License <input type="checkbox"/> Change of Name</p> <p><input type="checkbox"/> Merger <input type="checkbox"/> Other _____</p> <p>US. GOVERNMENT MAR 23 2001 (For Use ONLY by U.S. Government Agencies)</p> <p><input type="checkbox"/> Departmental File <input type="checkbox"/> Secret File</p> <p>Total No. of pages of conveyance document including attachments _____</p>
<p>4. Name of conveying party(ies):</p> <p>¹Johnson, Barry L. ²Patel, Mona ³Rodgers, James D. ⁴Wang, Haisheng ⁵Tarby, Christine M. ⁶Bakthavatchalam, Rajogopal</p> <p>Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p> <p>Execution Date: ¹12/18/2000 ²12/22/2000 ³12/18/2000 ⁴12/18/2000 ⁵12/18/2000 ⁶1/3/2001</p>	<p>5. Name and address of receiving party(ies):</p> <p>DUPONT PHARMACEUTICALS COMPANY CHESTNUT RUN PLAZA 974 CENTRE ROAD WILMINGTON, DELAWARE 19805</p> <p>Additional name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>
<p>5. Application number(s) or patent number(s):</p> <p>If this document is being filed together with a new application, the execution date of the application is:</p> <p>A. Patent Application No.(s): <u>09/691,249</u> B. Patent No.(s): _____</p> <p>Docket No.: <u>PH-7104</u></p> <p>Additional numbers attached: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</p>	
<p>6. Correspondent Name & Address:</p> <p>MARY K. VANATTEN E. I. DU PONT DE NEMOURS AND COMPANY LEGAL-PATENTS 1007 MARKET STREET WILMINGTON, DELAWARE 19898</p>	<p>7. Total number of applications and patents involved: <u>1</u></p> <p>8. Total fee (37 CFR 3.41) <u>\$40.00</u></p> <p><input type="checkbox"/> Enclosed (Check No.: _____)</p> <p><input checked="" type="checkbox"/> Authorized to be charged to deposit account</p> <p>9. Deposit account number: <u>04-1928</u> (Attach duplicate copy of this page if paying by deposit account)</p>
<p align="center">DO NOT USE THIS SPACE</p>	
<p>10. Statement and signature.</p> <p>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</p> <p>CAROL REEDER <u>Carol Reeder</u> <u>3/16/2001</u> SENIOR LEGAL CLERK Signature Date</p> <p>04/16/2001 LABELER 00000024 041928 09691249 01 PH-551 40.00 US</p> <p align="right">Total number of pages comprising cover sheet: <u>1</u></p>	

PATENT
REEL: 012151 FRAME: 0310

PATENT APPLICATION ASSIGNMENT

We, the undersigned

Hereby declare that

We are the true and first inventors of an invention entitled TRICYCLIC COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS (and which is identified as Case Number PH-7104) and which is disclosed in an application for Letters Patent in the United States of America.


For valuable consideration, the receipt and adequacy of which is hereby acknowledged and in fulfillment of our pre-existing obligation of assignment, we hereby:

I. Sell, assign, and transfer unto **DuPont Pharmaceuticals Company**, a General Partnership organized and existing under the laws of the State of Delaware in the United States of America and having its principal place of business at Chestnut Run Plaza, 974 Centre Road, Wilmington, Delaware 19805, hereinafter referred to as the assignee, (A) the sole and entire right, and interest in and to: (1) the aforesaid application for Letters Patent, (2) any priority rights derived from the aforesaid application for Letters Patent by virtue of intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, (3) any and all of our inventions, whether joint or sole, disclosed in the aforesaid application for Letters Patent, (4) any and all applications for Letters Patent for any such inventions in any country whatsoever, (5) any and all patents for any such inventions in any country whatsoever; and (B) the sole right to (1) file such applications in its name or ours, (2) file such applications under the aforesaid International Convention or other treaty or understanding, (3) have said patents granted in its name or ours, and (4) enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future; and

II. Agree, whenever requested, to communicate to said assignee, its successors, assigns, and legal representatives, any facts known to us respecting said rights, to testify in any legal proceeding respecting said rights, to execute all applications, papers or instruments necessary or required by said assignee, its successors, assigns and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid said assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions in any and all countries.

We further authorize our attorney/patent agent to insert below* the application number and filing date of the aforesaid United States application now identified as Case Number. After the same shall have been made known to him/her by the United States Patent Office.


Date: 12/18/00

 (L.S.)
Barry L. Johnson


Date: _____

(L.S.)
Mona Patel


Date: 12/18/00

 (L.S.)
James D. Rodgers

Date: _____

 (L.S.)
Haisheng Wang

Date: 12/18/00

 (L.S.)
Christine M. Tarby

Date: 12/18/00

(L.S.)
Rajagopal Bakthavatchalam

*The application referred to above (Case No. PH-7104) was filed in the United States Patent Office on October 18, 2000, and was given Application No. 09/691,249.

This insertion made by me this 11 day of January, 2001


ATTORNEY/PATENT AGENT FOR APPLICANTS

PATENT APPLICATION ASSIGNMENT

We, the undersigned

Hereby declare that

We are the true and first inventors of an invention entitled TRICYCLIC COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS (and which is identified as Case Number PH-7104) and which is disclosed in an application for Letters Patent in the United States of America.

For valuable consideration, the receipt and adequacy of which is hereby acknowledged and in fulfillment of our pre-existing obligation of assignment, we hereby:

I. Sell, assign, and transfer unto **DuPont Pharmaceuticals Company**, a General Partnership organized and existing under the laws of the State of Delaware in the United States of America and having its principal place of business at Chestnut Run Plaza, 974 Centre Road, Wilmington, Delaware 19805, hereinafter referred to as the assignee, (A) the sole and entire right, and interest in and to: (1) the aforesaid application for Letters Patent, (2) any priority rights derived from the aforesaid application for Letters Patent by virtue of intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, (3) any and all of our inventions, whether joint or sole, disclosed in the aforesaid application for Letters Patent, (4) any and all applications for Letters Patent for any such inventions in any country whatsoever, (5) any and all patents for any such inventions in any country whatsoever; and (B) the sole right to (1) file such applications in its name or ours, (2) file such applications under the aforesaid International Convention or other treaty or understanding, (3) have said patents granted in its name or ours, and (4) enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future; and

II. Agree, whenever requested, to communicate to said assignee, its successors, assigns, and legal representatives, any facts known to us respecting said rights, to testify in any legal proceeding respecting said rights, to execute all applications, papers or instruments necessary or required by said assignee, its successors, assigns and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid said assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions in any and all countries.

We further authorize our attorney/patent agent to insert below* the application number and filing date of the aforesaid United States application now identified as Case Number. After the same shall have been made known to him/her by the United States Patent Office.

Date: _____

(L.S.)

Barry L. Johnson

Date: _____

(L.S.)

James D. Rodgers

Date: _____

(L.S.)

Christine M. Tarby

Date: 12-22-2000

Mona Patel
(L.S.)

Mona Patel

Date: _____

(L.S.)

Haisheng Wang

Date: _____

(L.S.)

Rajagopal Bakthavatchalam

*The application referred to above (Case No. PH-7104) was filed in the United States Patent Office on October 18, 2000, and was given Application No. 09/691,249.

This insertion made by me this 11 day of January, 2001

Mary Van Atta
ATTORNEY/PATENT AGENT FOR APPLICANTS

PATENT APPLICATION ASSIGNMENT

We, the undersigned

Hereby declare that

We are the true and first inventors of an invention entitled TRICYCLIC COMPOUNDS USEFUL AS HIV REVERSE TRANSCRIPTASE INHIBITORS (and which is identified as Case Number PH-7104) and which is disclosed in an application for Letters Patent in the United States of America.

For valuable consideration, the receipt and adequacy of which is hereby acknowledged and in fulfillment of our pre-existing obligation of assignment, we hereby:

I. Sell, assign, and transfer unto **DuPont Pharmaceuticals Company**, a General Partnership organized and existing under the laws of the State of Delaware in the United States of America and having its principal place of business at Chestnut Run Plaza, 974 Centre Road, Wilmington, Delaware 19805, hereinafter referred to as the assignee, (A). the sole and entire right, and interest in and to: (1) the aforesaid application for Letters Patent, (2) any priority rights derived from the aforesaid application for Letters Patent by virtue of intellectual property for any and all member countries of the aforesaid International Convention or other treaty or understanding, (3) any and all of our inventions, whether joint or sole, disclosed in the aforesaid application for Letters Patent, (4) any and all applications for Letters Patent for any such inventions in any country whatsoever, (5) any and all patents for any such inventions in any country whatsoever; and (B) the sole right to (1) file such applications in its name or ours, (2) file such applications under the aforesaid International Convention or other treaty or understanding, (3) have said patents granted in its name or ours, and (4) enforce said patents and to sue for and recover profits and damages for any and all infringements thereof whether past or future; and

II. Agree, whenever requested, to communicate to said assignee, its successors, assigns, and legal representatives, any facts known to us respecting said rights, to testify in any legal proceeding respecting said rights, to execute all applications, papers or instruments necessary or required by said assignee, its successors, assigns and legal representatives, to carry into effect any of the provisions of this instrument, and generally to do everything possible to aid said assignee, its successors, assigns, and legal representatives to obtain and enforce proper patent protection for said inventions in any and all countries.

We further authorize our attorney/patent agent to insert below* the application number and filing date of the aforesaid United States application now identified as Case Number. After the same shall have been made known to him/her by the United States Patent Office.

Date: _____

(L.S.)

Barry L. Johnson

Date: _____

(L.S.)

James D. Rodgers

Date: _____

(L.S.)

Christine M. Tarby

Date: _____

(L.S.)

Mona Patel

Date: _____

(L.S.)

Haisheng Wang

Date: Jan 03, 2001

Rajagopal Bakthavatchalam (L.S.)

Rajagopal Bakthavatchalam

*The application referred to above (Case No. PH-7104) was filed in the United States Patent Office on October 18, 2000, and was given Application No. 09/691,249.

This insertion made by me this 11 day of January, 2001

Mary Van Der
ATTORNEY/PATENT AGENT FOR APPLICANTS